GlassScriptPhysician profile
Tymwa Dixon
NPI 1881620003
$1,328.45
in general payments reported to CMS, 2019-2025
19 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $77.37 · 2021: $80.67 · 2022: $81.30 · 2023: $68.79 · 2024: $157 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $262.31 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $246.46 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.99 | 2019 | |
| Sumitomo Pharma America, INC. | $110.60 | 2024-2025 | Gemtesa |
| Ardelyx, INC. | $78.76 | 2025 | Ibsrela |
| Astellas Pharma US INC | $75.23 | 2019-2020 | |
| Pfizer INC. | $72.51 | 2019-2021 | |
| Novo Nordisk INC | $70.56 | 2019-2022 | |
| Lundbeck LLC | $44.46 | 2024-2025 | Rexulti |
| Abbvie INC. | $33.51 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $30.36 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.70 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $25.29 | 2022 | |
| Merck Sharp & Dohme LLC | $25.01 | 2019 | |
| Ibsa Pharma INC. | $16.53 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.40 | 2019 | |
| Amgen INC. | $13.56 | 2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $12.96 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tymwa Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.